Phase II trial of piroxantrone in metastatic gastric adenocarcinoma |
| |
| Authors: | Richard Pazdur Beth Bready Anthony J. Scalzo James E. Brandof David R. Close Sharon Kolbye Rodger J. Winn |
| |
| Affiliation: | (1) Divisions of Medicine and Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA;(2) Syracuse Community Oncology Program, Syracuse, NY, USA;(3) Spartanburg Community Oncology Program, Spartanburg, SC, USA;(4) Texas Tech University Health Science Center and Texas Clinical Oncology Network, Lubbock, TX, USA |
| |
| Abstract: | Summary Piroxantrone, a synthetic intercalating agent, was studied in patients with advanced, measurable gastric adenocarcinoma who had not received prior chemotherapy. The starting piroxantrone dose was 150 mg/m2 given intravenously over 1 hour on day 1 and repeated every 21 days. Response and toxicity could be evaluated in 15 patients. No complete, partial, or minor responses were observed. Toxic effects included granulocytopenia, anemia, vomiting, nausea, anorexia, fatigue, stomatitis, alopecia, hyperbilirubinemia, and increased alkaline phosphatase levels. At the stated dose and schedule, piroxantrone does not possess significant activity against advanced gastric cancer. |
| |
| Keywords: | gastric carcinoma piroxantrone stomach carcinoma |
| 本文献已被 SpringerLink 等数据库收录！ |
|
